Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - benralizumab - ażma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - fasenra huwa indikat bħala żieda fit-trattament ta 'manteniment f'pazjenti adulti bi ħsara severa eżinofilika-ażma mhux ikkontrollati adegwatament, minkejja doża għolja ta' kortikosterojdi meħuda man-nifs biż-żieda fit-tul li jaġixxu β-agonisti.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid, metformin hydrochloride - diabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - ażma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol, mometasone furoate - ażma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol acetate, mometasone furoate - ażma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - ażma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - maintenance treatment of asthma in adults whose disease is not adequately controlled.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

teva b.v. - salmeterol xinafoate, fluticasone propionate - ażma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - bropair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

teva b.v. - fluticasone propionate, salmeterol xinafoate - ażma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - seffalair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

angelini pharma s.p.a - cenobamate - epilessija - anti-epilettiċi, - adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - rifjut ta 'graft - immunosoppressanti - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.